Published 2017 | Version v1
Publication

Weight gain: A possible side effect of all antiretrovirals

Description

Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P = .0004), elvitegravir (P = .004), darunavir (P = .0006), and rilpivirine (P = .029). BMI gain correlated with low baseline BMI (P = .002) and older age (P = .0007) in Centers for Disease Control and Prevention stages A/B, with lower BMI (P = .005) and CD4+ T-cell count (P = .007) at enrollment in stage C.

Additional details

Identifiers

URL
http://hdl.handle.net/11567/954302
URN
urn:oai:iris.unige.it:11567/954302

Origin repository

Origin repository
UNIGE